The mucopolysaccharidoses: a success of molecular medicine

Lorne A. Clarke

doi:10.1017/S1462399408000550

The mucopolysaccharidoses: a success of molecular medicine

Published online by Cambridge University Press: 18 January 2008

Lorne A. Clarke

Show author details

Lorne A. Clarke: Affiliation:
University of British Columbia, Child and Family Research Institute, Department of Medical Genetics, 4500 Oak Street, Room C234, Vancouver, British Columbia, Canada, V6H 3N1. Tel: +1 604 875 3526; Fax: +1 604 875 2376; E-mail: [email protected]

Article contents

Abstract
References

Get access

Rights & Permissions

Abstract

The mucopolysaccharidoses represent a devastating group of lysosomal storage diseases affecting approximately 1 in 25 000 individuals. Advances in biochemistry and genetics over the past 25 years have resulted in the identification of the key hydrolases underlying the mucopolysaccharidoses, with subsequent isolation and characterisation of the genes involved. Ultimately these advances have led to the recent development of specific treatment regimens for some of the mucopolysaccharidoses, in the form of direct enzyme replacement. Direct replacement of the defective gene product has been attempted for very few genetic disorders, and thus the experience gained in the lysosomal storage diseases by the development, evaluation and integration of treatment regimens into healthcare is instructive for other rare genetic disorders. This review focuses on the pathophysiology of the mucopolysaccharidoses and highlights the complex biochemical and physiological perturbations that underlie the disease phenotype.

Type: Review Article
Information: Expert Reviews in Molecular Medicine , Volume 10 , October 2008 , e1

DOI: https://doi.org/10.1017/S1462399408000550 [Opens in a new window]
Copyright: Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Neufeld, E.S. and Muenzer, J. (2007) The mucopolysaccharidoses. In the Online Metabolic and Molecular Bases of Inherited Disease (Scriver, C.R. et al. eds), Chapter 136, McGraw-Hill. http://genetics.accessmedicine.com/mmbid/public/Google Scholar

2McKusick, V.A. et al. (1965) The genetic mucopolysaccharidoses. Medicine 44, 445-483CrossRef Google Scholar PubMed

3McKusick, V.A. (1966) Heritable Disorders of Connective Tissue, MosbyGoogle Scholar

4Roubicek, M., Gehler, J. and Spranger, J. (1985) The clinical spectrum of α-L-iduronidase deficiency. Am J Med Genet 20, 471-481CrossRef Google Scholar PubMed

5Young, I.D. et al. (1982) A clinical and genetic study of Hunter's syndrome. 1. Heterogeneity. J Med Genet 6, 401-407CrossRef Google Scholar

6Ashton, L.J. et al. (1992) Immunoquantification and enzyme kinetics of alpha-L-iduronidase in cultured fibroblasts from normal controls and mucopolysaccharidosis type I patients. Am J Hum Gene 50, 787-794Google Scholar PubMed

7Parkinson-Lawrence, E. et al. (2005) Analysis of normal and mutant iduronate-2-sulphatase conformation. Biochem J 386, 395-400CrossRef Google Scholar PubMed

8Fuller, M. et al. (2005) Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab 84, 18-24CrossRef Google Scholar PubMed

9Beesley, C.E. et al. (2001) Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet 109, 503-511Google Scholar PubMed

10Bunge, S. et al. (1995) Mucopolysaccharidosis type I: indentification of 13 novel mutations of the α-L-iduronidase gene. Hum Mutat 6, 91-94CrossRef Google Scholar

11Terlato, N.J. and Cox, G.F. (2003) Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med 5, 286-294CrossRef Google Scholar PubMed

12Brooks, D.A. et al. (2001) Glycosidase active site mutations in human alpha-L-iduronidase. Glycobiology 11, 741-750CrossRef Google Scholar PubMed

13Timms, K.M. et al. (1997) Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum Mol Genet 6, 479-486CrossRef Google Scholar PubMed

14Vafiadaki, E. et al. (1998) Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease). Arch Dis Child 79, 237-241CrossRef Google Scholar PubMed

15Froissart, R. et al. (2002) Mucopolysaccharidosis type II–genotype/phenotype aspects. Acta Paediatr Suppl 91, 82-87CrossRef Google Scholar PubMed

16Karageorgos, L. et al. (2007) Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 28, 897-903CrossRef Google Scholar PubMed

17Litjens, T. et al. (1996) Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet 58, 1127-1134Google Scholar PubMed

18Rempel, B.P., Clarke, L.A. and Withers, S.G. (2005) A homology model for human α-L-iduronidase: insights into human disease. Hum Mol Genet 85, 28-37Google Scholar PubMed

19Treacy, E., Childs, B. and Scriver, C.R. (1995) Response to treatment in hereditary metabolic disease: 1993 survey and 10-year comparison. Am J Hum Genet 56, 359-367Google Scholar

20Walkley, S.U. and March, P.A. (1993) Biology of neuronal dysfunction in storage disorders. J Inher Metab Dis 16, 284-287CrossRef Google Scholar PubMed

21Walkley, S.U. (2004) Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol 15, 433-444CrossRef Google Scholar PubMed

22Walkley, S.U., Zervas, M. and Wiseman, S. (2000) Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons. Cereb Cortex 10, 1028-1037CrossRef Google Scholar PubMed

23Walkley, S.U. et al. (2005) Abnormal neuronal metabolism and storage in mucopolysaccharidosis type VI (Maroteaux-Lamy) disease. Neuropathol Appl Neurobiol 31, 536-544CrossRef Google Scholar PubMed

24Jolly, R.D. and Walkley, S.U. (1997) Lysosomal storage diseases of animals: an essay in comparative pathology. Vet Pathol 34, 527-548CrossRef Google Scholar PubMed

25Turnbull, J., Powell, A. and Guimond, S. (2001) Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 11, 75-82CrossRef Google Scholar PubMed

26Bülow, H.E. and Hobert, O. (2006) The molecular diversity of glycosaminoglycans shapes animal development. Annu Rev Cell Dev Biol 22, 375-407CrossRef Google Scholar PubMed

27Taylor, K.R. and Gallo, R.L. (2006) Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 20, 9-22CrossRef Google Scholar PubMed

28Jackson, R.L., Busch, S.J. and Cardin, A.D. (1991) Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71, 481-539CrossRef Google Scholar PubMed

29Prydz, K. and Dalen, K.T. (2000) Synthesis and sorting of proteoglycans. J Cell Sci 113, 193-205CrossRef Google Scholar PubMed

30Bishop, J.R., Schuksz, M. and Esko, J.D. (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1037CrossRef Google Scholar PubMed

31Perrimon, N. and Bernfield, M. (2001) Cellular functions of proteoglycans-an overview. Semin Cell Dev Biol 12, 65-67CrossRef Google Scholar PubMed

32Bernfield, M. et al. (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729-777CrossRef Google Scholar PubMed

33Yamaguchi, Y. (2001) Heparan sulfate proteoglycans in the nervous system: their diverse roles in neurogenesis, axon guidance, and synaptogenesis. Semin Cell Dev Biol 12, 99-106CrossRef Google Scholar PubMed

34Handel, T.M. et al. (2005) Regulation of protein function by glycosaminoglycans—as exemplified by chemokines. Annu Rev Biochem 74, 385-410CrossRef Google Scholar PubMed

35Wraith, J.E. et al. (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (Laronidase). J Pediatr 144, 581-588CrossRef Google Scholar PubMed

36Muenzer, J. et al. (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8, 465-473CrossRef Google Scholar PubMed

37Harmatz, P. et al. (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blinded, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or RHASB) and follow-on, open-label extension study. J Pediatr 148, 533-539CrossRef Google Scholar PubMed

38Sands, M.S. et al. (1994) Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest 93, 2324-2331CrossRef Google Scholar PubMed

39Guffon, N. et al. (1998) Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 133, 119-125CrossRef Google Scholar PubMed

40Peters, C. et al. (1996) Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 87, 4894-4902CrossRef Google Scholar PubMed

41Peters, C. et al. (1998) Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group Blood 91, 2601-2608Google Scholar PubMed

42Souillet, G. et al. (2003) Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transpl 31, 1105-1117CrossRef Google Scholar PubMed

43Staba, S.L. et al. (2004) Cord-blood transplants from unrelated donors in patients with Hurler syndrome. N Eng J Med 350, 1960-1969CrossRef Google Scholar

44Vellodi, A. et al. (1997) Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 76, 92-99CrossRef Google Scholar PubMed

45Whitley, C.B. et al. (1993) Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet 46, 209-218CrossRef Google Scholar PubMed

46Guffon, N. et al. (2001) Outcome of bone marrow transplantation in eight patients with Hunter disease. J Inherit Metab Dis 24, 172Google Scholar

47Vellodi, A. et al. (1999), Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 22, 638-648CrossRef Google Scholar PubMed

48Sivakumur, P. and Wraith, J.E. (1999) Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J Inherit Metab Dis 22, 849-850CrossRef Google Scholar PubMed

49Grewal, S.S. et al. (2005) Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med 7, 143-146CrossRef Google Scholar PubMed

50Wraith, J.E. et al. (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human α-L-iduronidase (Laronidase). Pediatrics 120, e37-e46CrossRef Google Scholar PubMed

51Beck, M. (2007) New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 121, 1-22CrossRef Google Scholar PubMed

52Sands, M.S. and Davidson, B.L. (2006) Gene therapy for lysosomal storage diseases. Mol Ther. 13, 839-849CrossRef Google Scholar PubMed

53Vogler, C. et al. (2001) Murine mucopolysaccharidosis VII: impact of therapies on the phenotype, clinical course, and pathology in a model of a lysosomal storage disease. Pediatr Dev Pathol. 4, 421–33CrossRef Google Scholar

54Li, H.H. et al. (1999) Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding α-N-acetylglucosaminidase. Proc Natl Acad Sci U S A 96, 14505-14510CrossRef Google Scholar PubMed

55Vogler, C. et al. (2005) Early onset of lysosomal storage disease in murine model of mucopolysaccharidosis type VII: undegraded substrate accumulates in many tissues in the fetus and very young MPS VII mouse. Pediatr Devel Pathol 8, 453-462CrossRef Google Scholar PubMed

56Bhaumik, M. et al. (1999) A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9, 1389-1396CrossRef Google Scholar PubMed

57Russell, C. et al. (1998) Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 53, 349–61CrossRef Google Scholar PubMed

58Nuttall, J.D. et al. (1999) Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Calcif Tissue Int 65, 47-52CrossRef Google Scholar

59McGlynn, R., Dobrenis, K. and Walkley, S.U. (2004) Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol 480, 415-426CrossRef Google Scholar PubMed

60Tomatsu, S. et al. (2005) Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 28, 743-757CrossRef Google Scholar PubMed

61Ramsay, S.L. et al. (2004) Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionization tandem spectrometry: in utero indicators of lysosomal storage diseases. Mol Genet Metab 83, 231-238CrossRef Google Scholar PubMed

62Greenwood, R.S. et al. (1978) Sanfilippo A syndrome in the fetus. Clin Genet 13, 241-250CrossRef Google Scholar PubMed

63Wiesmann, U.N. et al. (1980) Neonatal mucopolysaccharidosis II (Hunter): a pathogenetic study. Pediatr Res 14, 749-756CrossRef Google Scholar

64Casal, M.L. and Wolfe, J.H. (2000) Mucopolysaccharidosis type VII in the developing mouse fetus. Pediatr Res 47, 750-756CrossRef Google Scholar PubMed

65Jones, M.Z. et al. (2004) Caprine mucopolysaccharidosis IIID. J Mol Neurosci 24, 277-291CrossRef Google Scholar PubMed

66Clarke, L.A. et al. (1997) Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum Mol Genet. 6, 503-511CrossRef Google Scholar PubMed

67Beutler, E. (2006) Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 88 208-215CrossRef Google Scholar PubMed

68Van Hoof, F. and Hers, H.G. (1968) Eur J Biochem 7, 34-44CrossRef Google Scholar

69Sands, M.S. et al. (1994) Enzyme replacement therapy for murine mucopolysaccharidosis type VII.J. Clin. Invest. 93, 2324-2331CrossRef Google Scholar

70Avila, J.L. and Convit, J. (1975) Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro. Biochem J 152, 57-64CrossRef Google Scholar PubMed

71Canstantopoulous, G. and Dekaban, A.S. (1978) Neurochemistry of the mucopolysaccharidoses: brain lipids and lysosomal enzymes in patients with four type of mucopolysaccharidosis and in normal controls. J Neurochem 30, 965-973CrossRef Google Scholar

72Jones, M.Z. et al. (1997) Human mucopolysaccharidosis IIID: clinical, biochemical, morphological and immunohistochemical characteristics. J Neuropathol Exp Neurol 56, 1158-1167CrossRef Google Scholar PubMed

73Jones, M.Z. et al. (1998) Caprine mucopolysaccharidosis-IIID: clinical, biochemical, morphological and immunohistochemical characteristics. J Neuropathol Exp Neurol 57, 148-157CrossRef Google Scholar PubMed

74Liour, S.S. et al. (2001) Metabolic studies of glycosphingolipid accumulation in mucopolysaccharidosis IIID. Mol Genet Metab 72, 239-247CrossRef Google Scholar PubMed

75Walkley, S.U. (2004) Pathologic cascades and brain dysfunction. In Lysosomal Disorders of the Brain. (Platt, F.M. and Walkley, S.U., eds), pp 290-324, OxfordCrossRef Google Scholar

76Walkley, S.U. and Suzuki, K. (2004) Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochem Biophys Acta 1685, 48-62Google Scholar PubMed

77Pagano, R.E. et al. (2000) Membrane traffic in sphingolipid diseases. Traffic 1, 807-815CrossRef Google Scholar PubMed

78Jeyakumar, M. et al. (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126, 974-987CrossRef Google Scholar PubMed

79Myerowitz, R. et al. (2002) Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum Mol Genet 11, 1343-1350CrossRef Google Scholar PubMed

80Langmade, S.J. et al. (2006) Pregnane X receptor (PXR) activation: A mechanism for neuroprotection in a mouse model of Niemann–Pick C disease. Proc Natl Acad Sci U S A 103, 13807-13812CrossRef Google Scholar

81Settembre, C. et al. (2007) Systemic inflammation and neurodegeneration in a mouse model of multiple sulfatase deficiency. Proc Natl Acad Sci U S A 104, 4506-4511CrossRef Google Scholar

82Ohmi, K. et al. (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci U S A 100, 1902-1907CrossRef Google Scholar PubMed

83Jeyakumar, M. et al. (2004) NSAIDs increase survival in the sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol 56, 642-649CrossRef Google Scholar PubMed

84Ko, D. et al. (2005), Cell-autonomous death of cerebellar purkinje neurons with autophagy in Niemann-Pick type C disease. PLoS Genet 1, 81-95Google Scholar PubMed

85Simonaro, C.M., Haskins, M.E. and Schuchman, E.H. (2001) Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 81, 1319-1328CrossRef Google Scholar PubMed

86Simonaro, C.M. et al. (2005) Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 57, 701-707CrossRef Google Scholar PubMed

87Mulloy, B. and Rider, C.C. (2006) Cytokines and proteoglycans: an introductory overview. Biochem Soc T 34, 409-413CrossRef Google Scholar PubMed

88Parish, C.R. (2006) The role of heparin sulphate in inflammation. Nat Rev Immunol 6, 633-643CrossRef Google Scholar

89Randall, D.R. et al. (2006) Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol Genet Metab 88, 235-243CrossRef Google Scholar PubMed

90Maekawa, H., Sato, H. and Tollefsen, D.M. (2000) Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex. Thromb Res 100, 443-451CrossRef Google Scholar PubMed

91Verhamme, I.M., Bock, P.E. and Jackson, C.M. (2004) The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II. J Biol Chem 279, 9785-9795CrossRef Google Scholar PubMed

92Pike, R.N. et al. (2005) Control of the coagulation system by serpins getting by with a little help from glycosaminoglycans. FEBS J 272, 4842-4851CrossRef Google Scholar PubMed

93Meins, M. et al. (2001) Progressive neuronal and motor dysfunction in mice overexpressing the serine protease inhibitor protease nexin-1 in postmitotic neurons. J Neurosci 21, 8830-8841CrossRef Google Scholar PubMed

94Ginsberg, S.D. et al. (1999) Accumulation of intracellular amyloid-beta peptide (A beta 1–40) in mucopolysaccharidosis brains. J Neuropathol Exp Neurol 58, 815-824CrossRef Google Scholar PubMed

95Watanabe, N. et al. (2004) Glypican-1 as an Abeta binding HSPG in the human brain: its localization in DIG domains and possible roles in the pathogenesis of Alzheimer's disease. FASEB J 18, 1013-1015CrossRef Google Scholar PubMed

96Mayer-Sonnenfeld, T. et al. (2005) The metabolism of glycosaminoglycans is impaired in prion diseases. Neurobiol Dis 20, 738-743CrossRef Google Scholar

97Ryazantsev, S. et al. (2007) Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B. Mol Genet Metab 90, 393-401CrossRef Google Scholar PubMed

98Hinek, A. and Wilson, S.E. (2000) Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Path 156, 925-938CrossRef Google Scholar PubMed

99Kozel, B.A., Ciliberto, C.H. and Mecham, R.P. (2004) Deposition of tropoelastin into the extracellular matrix requires a competent elastic fiber scaffold but not live cells. Matrix Biol 23, 23-34CrossRef Google Scholar

100Hinek, A. et al. (2004) Retrovirally mediated overexpression of versican v3 reverses impaired elastogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. Am J Pathol 164, 119-131CrossRef Google Scholar PubMed

101Li, Z. et al. (2004) Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem 279, 5470-5479CrossRef Google Scholar PubMed

102Selent, J. et al. (2007) Selective inhibition of the collagenase activity of cathepsin K. J Biol Chem 282, 16492-16501CrossRef Google Scholar PubMed

103Jackson, R.A., Nurcombe, V. and Cool, S.M. (2006) Coordinated fibroblast growth factor and heparin sulfate regulation of osteogenesis. Gene 379, 79-91CrossRef Google Scholar PubMed

104Shinmyouzu, K. et al. (2007) Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-κB ligand. Biochem Biophys Res Commun 354, 447-452CrossRef Google Scholar

105Rauch, U. and Kappler, J. (2006) Chondroitin/Dermatan sulfates in the central nervous system: their structures and functions in health and disease. Adv Pharmacol. 53, 337-356CrossRef Google Scholar PubMed

106Huntington, J.A. (2003) Mechanisms of glycosaminoglycan activation of the serpins inhemostasis. J Thromb Haemost 1, 1535-1549CrossRef Google Scholar

107Roughley, P.J. (2006) The structure and function of cartilage proteoglycans. Eur Cell Mater 12, 92-101CrossRef Google Scholar PubMed

108Chang, X., Yamada, R. and Yamamoto, K. (2005) Inhibition of antithrombin by hyaluronic acid may be involved in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 7, R268-R273CrossRef Google Scholar PubMed

109Knox, S.M. and Whitelock, J.M. (2006) Perlecan: how does one molecule do so many things? Cell Mol Life Sci 63, 2435-2445CrossRef Google Scholar PubMed

110Gomes, R.R. Jr, Farach-Carson, M.C. and Carson, D.D. (2004) Perlecan functions in chondrogenesis: insights from in vitro and in vivo models. Cells Tissues Organs 176, 79-86CrossRef Google Scholar PubMed

111Gautam, M. et al. (1996) Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 85, 525–35CrossRef Google Scholar PubMed

112Marneros, A.G. and Olsen, B.R. (2005) Physiological role of collagen XVIII and endostatin. FASEB J 19, 716-728CrossRef Google Scholar PubMed

113Watanabe, H., Yamada, Y. and Kimata, K. (1998) Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function. J Biochem 124, 687-693CrossRef Google Scholar PubMed

114Yoon, J.H. and Halper, J. (2004) Tendon proteoglycans: biochemistry and function. J Musculoskelet Neuronal Interact 5, 22-34Google Scholar

115Yamaguchi, Y. (2001) Heparan sulfate proteoglycans in the nervous system: their diverse roles in neurogenesis, axon guidance, and synaptogenesis. Semin Cell Dev Biol 12, 99-106CrossRef Google Scholar PubMed

116Bovolenta, P. and Fernaud-Espinosab, I. (2000) Nervous system proteoglycans as modulators of neurite outgrowth. Prog Neurobiol 61, 113-132CrossRef Google Scholar PubMed

117Knudson, C.B. and Knudson, W. (2001) Cartilage proteoglycans. Semin Cell Dev Biol 12, 69-78CrossRef Google Scholar PubMed

118Chakravarti, S. (2006) Focus on molecules: keratocan (KERA). Exp Eye Res 82, 183-184CrossRef Google Scholar PubMed

119Kakkis, E.D. et al. (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344, 182-188CrossRef Google Scholar PubMed

120Sifuentes, M. et al. (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90, 171-180CrossRef Google Scholar

121Muenzer, J. et al. (2007) A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 90, 329-337CrossRef Google Scholar PubMed

122Harmatz, P. (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144, 574-580CrossRef Google Scholar PubMed

123Harmatz, P. (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115, e681-e689CrossRef Google Scholar

Article contents

The mucopolysaccharidoses: a success of molecular medicine

Abstract

Access options

References

References

Further reading, resources and contacts

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

The mucopolysaccharidoses: a success of molecular medicine

Abstract

Access options

References

References

Further reading, resources and contacts

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests